Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease Clinical Trial

Official title:

Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)

Clinical Trial Details — Status: Approved for marketing

Administrative data

• NCT number: NCT01476163
• Other study ID #: AT1001-188
• Status: Approved for marketing

Study information

• Verified date: January 2019
• Source: Amicus Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry disease. Treatment is open label for 6 months with renewal every 6 months.

Description:

This Physician Initiated Request program allows physicians to request permission from Amicus to receive migalastat HCl for specific patients with Fabry disease who have a mutation amenable to this treatment, who do not have access to available treatment alternatives, or do not meet requirements for participation in an existing migalastat clinical study. Up to 20 patients worldwide may be treated. Patients must meet specific criteria to receive Amicus permission for participation. Key criteria for participation include: 16-74 years old; Confirmed GLA gene mutation shown to be responsive to migalastat; Have no treatment option because either unsuitable for enzyme replacement therapy (ERT) or unable to access ERT. Requirements for sufficient kidney function. If permission is granted, initial approval is for a 6 month supply of migalastat HCl with renewal every 6 months available upon meeting continued eligibility.

Recruitment information / eligibility

• Status: Approved for marketing
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 74 Years

Eligibility

Inclusion Criteria:

• Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic kidney (HEK-293) cell-based assay

• 16-74 years of age

• Strong clinical indication for treatment of Fabry disease

• No other treatment option including either unsuitable for ERT or unable to access ERT

• Appropriate female and male contraception

• Willing to receive treatment with migalastat HCl via this program including having signed an authorization for sharing clinical data

Exclusion Criteria:

• Estimated glomerular filtration rate (eGFR) or GFR <30 mL/minute

• Scheduled for renal or other organ transplant or replacement therapy

• Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy FABRAZYME® (agalsidase beta) or REPLAGAL™ (agalsidase alpha)

• Contraindication to migalastat, i.e., sensitivity to other iminosugar such as miglustat, miglitol

• Treated with another investigational drug within 30 days of start of migalastat HCl treatment

• Unable to comply with study requirements or deemed otherwise unsuitable for study entry in the opinion of the investigator.

Related Conditions & MeSH terms

• Fabry Disease

Intervention

Drug:
• migalastat HCl
150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl

Locations

Country	Name	City	State
Australia	Royal Melbourne Hospital	Parkville	Victoria
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	CHOC Children's Hospital Division of Metabolic Disease	Orange	California
United States	Kidney Care and Transplant Services of New England	Springfield	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Amicus Therapeutics

Countries where clinical trial is conducted

United States,  Australia,